Relationship between corticosteroid exposure and plasma lipid levels in heart transplant recipients1

Becker, Davida; Chamberlain, Bruce; Swank, Robert T.; Hegewald, Michael G.; GIRARDET, R; Baughman, Kerrie; Kwiterovich, P.; Pearson, Thomas A.; Ettinger, Walter H.; RENLUND, D

doi:10.1016/0002-9343(88)90684-5

Cited by 4 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The effects of steroid treatment on serum lipids may vary depending on the daily dose and duration of steroid treatment (73). Corticosteroidtreated transplant recipients showed increased frequency of hypercholesterolemia and hypertriglyceridemia, with elevations of both LDL-C and HDL-C levels (74)(75)(76)(77). Short-term prospective studies of the effects of prednisone in healthy men and patients with various disorders requiring corticosteroid therapy have shown an increase in TC by 8-17% and an increase in HDL-C by 36-68%, with insignificant changes in LDL-C levels (78,79).…”

Section: Steroidmentioning

confidence: 99%

Secondary dyslipidemia: its treatments and association with atherosclerosis

Yanai

Yoshida

2021

GHM

View full text Add to dashboard Cite

Dyslipidemia is classified into primary and secondary types. Primary dyslipidemia is basically inherited and caused by single or multiple gene mutations that result in either overproduction or defective clearance of triglycerides and cholesterol. Secondary dyslipidemia is caused by unhealthy lifestyle factors and acquired medical conditions, including underlying diseases and applied drugs. Secondary dyslipidemia accounts for approximately 30-40% of all dyslipidemia. Secondary dyslipidemia should be treated by finding and addressing its causative diseases or drugs. For example, treatment of secondary dyslipidemia, such as hyperlipidemia due to hypothyroidism, by using statin without controlling hypothyroidism, may lead to myopathy and serious adverse events such as rhabdomyolysis. Differential diagnosis of secondary dyslipidemia is very important for safe and effective treatment. Here, we describe an overview about diseases and drugs that interfere with lipid metabolism leading to secondary dyslipidemia. Further, we show the association of each secondary dyslipidemia with atherosclerosis and the treatments for such dyslipidemia.

show abstract

Section: Steroidmentioning

confidence: 99%

Secondary dyslipidemia: its treatments and association with atherosclerosis

Yanai

Yoshida

2021

GHM

View full text Add to dashboard Cite

show abstract

Cardiac allograft vasculopathy: current concepts and treatment

Waller¹,

Brook²,

Nicholson³

2003

Transplant Int

View full text Add to dashboard Cite

Cardiac allograft vasculopathy (CAV) remains the leading limiting factor of patient and graft survival after the first post-operative year. The pathogenesis involves both immunological and non-immunological factors. Here, we present recent advances and discuss potential preventative and treatment regimens. A review of the current literature of heart transplantation, detailing molecular mechanisms, pharmacological risk factors and novel immunosuppression regimens was performed. Recent findings demonstrate the pivotal role of the endothelium, resulting in release of pro-fibrotic cytokines, recruitment of circulating leucocytes, proliferation of vascular smooth muscle cells, and deposition of extracellular matrix proteins (ECMs). The role of HMG-CoA reductase inhibitors and anti-hypertensives remains controversial, but there is increasing evidence advocating their prophylactic use. We can conclude that novel immunosuppressive agents such as rapamycin, mycophenolate mofetil and FTY-720 are experimental immunosuppressive agents that are undergoing evaluation in clinical trials. The prophylactic use of statins and anti-hypertensive drugs needs to be defined but needs to suggest potential strategies to prolong cardiac allograft survival.

show abstract

Serum lipids in children 3 to 5 years after kidney, liver, and heart transplantation

et al. 2004

View full text Add to dashboard Cite

Although dyslipidaemia is common after solid organ transplantation (Tx), there are few long-term studies in children. We investigated the prevalence of dyslipidaemia up to 5 years after Tx in 125 children on triple immunosuppression with one of three different well-functioning grafts, kidney, liver, and heart, and 181 controls. Total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and triglyceride (TG) concentrations were measured annually. Low-density lipoprotein cholesterol concentrations were also calculated. The risk factors for dyslipidaemia were determined at 3 years. There was a high prevalence of hypertriglyceridaemia in all three groups, 50% in the kidney transplantation (KTx) and heart transplantation (HTx) groups and 30% in the liver transplantation (LTx) group. In addition, 50% of KTx patients had high TC. In the Tx groups taken together, the following independent associations were observed: KTx and high pre-Tx TC were associated with high TC, high trough concentration of blood cyclosporine with low HDL-C, and older age at Tx accounted for higher TG. Dyslipidaemia, especially hypertriglyceridaemia, was common 3-5 years after Tx. The aetiology is multifactorial and depends on the transplanted organ.

show abstract

Relationship between corticosteroid exposure and plasma lipid levels in heart transplant recipients1

Cited by 4 publications

References 0 publications

Secondary dyslipidemia: its treatments and association with atherosclerosis

Secondary dyslipidemia: its treatments and association with atherosclerosis

Cardiac allograft vasculopathy: current concepts and treatment

Serum lipids in children 3 to 5 years after kidney, liver, and heart transplantation

Contact Info

Product

Resources

About